Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial.

Address: Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany.; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany.; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany.; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; University Hospital TU Dresden, Dresden, Germany.; Leipzig University Hospital, Leipzig, Germany.; Department of Internal Medicine II, University Hospital of Kiel, Kiel, Germany.; Department of Internal Medicine II, University Hospital of Frankfurt Main, Frankfurt am Main, Germany.; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Department of Medical Oncology and Hematology, Universitätsspital & Universität Zürich, Zürich, Switzerland.; The LOOP Zürich-Medical Research Center, Zürich, Switzerland.; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.; Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany. [email protected].; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany. [email protected].; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany. [email protected].; Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany. [email protected].; Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany. [email protected].; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. [email protected].; Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany. [email protected].